Delving into the Latest Updates on MEDI-7352 with Synapse

Overview

Basic Info

Drug Type

Bispecific antibody

Synonyms

Target

NGF x TNF-α

Action

inhibitors

Mechanism

NGF inhibitors(Nerve growth factor inhibitors), TNF-α inhibitors(Tumor necrosis factor α inhibitors)

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal Diseases

Active Indication

Osteoarthritis, Knee

Inactive Indication

Chronic PainDiabetic Neuropathies

Originator Organization

MedImmune LLC

Active Organization

AstraZeneca PLC

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This is a Phase IIb randomised, double-blind, placebo-controlled, dose-response study in participants with painful osteoarthritis (OA) of the knee. The study will assess the safety and efficacy of multiple doses of MEDI7352 compared to placebo, as well as the pharmacokinetics, pharmacodynamics and immunogenicity of MEDI7352 in participants with moderate to severe chronic pain persistent for 3 months or more not adequately controlled by standard of care treatments.

Start Date02 Dec 2020

Sponsor / Collaborator

AstraZeneca PLC

100 Clinical Results associated with MEDI-7352

Login to view more data

100 Translational Medicine associated with MEDI-7352

Login to view more data

100 Patents (Medical) associated with MEDI-7352

Login to view more data

100 Deals associated with MEDI-7352

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoarthritis, Knee	Phase 2	Estonia	AstraZeneca PLC	02 Dec 2020
Osteoarthritis, Knee	Phase 2	Poland	AstraZeneca PLC	02 Dec 2020
Osteoarthritis, Knee	Phase 2	Denmark	AstraZeneca PLC	02 Dec 2020
Osteoarthritis, Knee	Phase 2	Spain	AstraZeneca PLC	02 Dec 2020
Osteoarthritis, Knee	Phase 2	Germany	AstraZeneca PLC	02 Dec 2020
Diabetic Neuropathies	Phase 2	Hungary	AstraZeneca PLC	19 Nov 2018
Diabetic Neuropathies	Phase 2	Romania	AstraZeneca PLC	19 Nov 2018
Diabetic Neuropathies	Phase 2	Poland	AstraZeneca PLC	19 Nov 2018
Diabetic Neuropathies	Phase 2	United Kingdom	AstraZeneca PLC	19 Nov 2018
Diabetic Neuropathies	Phase 2	Denmark	AstraZeneca PLC	19 Nov 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04675034 (BESPOKE, CTgov)	Phase 2	Osteoarthritis, Knee	345	Placebo	wmticierwb(bftzuwjvtb) = tbatamijnb fsjywxtvxo (rppzbplzgc, tfkieahapf - hikijwxwaj) View more	-	10 Feb 2025
NCT03755934 (CTgov)	Phase 2	Diabetic Neuropathies	112	Placebo (Placebo)	ywbnunuerj(ioiqzxnypn) = ohmjnggolv ipcuuccmku (oolohaqjbm, banidmzmku - ocdwyatrim) View more	-	19 Sep 2024
NCT03755934 (CTgov)	Phase 2	Diabetic Neuropathies	112	MEDI7352 (MEDl7352 Low Dose)	ywbnunuerj(ioiqzxnypn) = bdjoqhzmlv ipcuuccmku (oolohaqjbm, yixxweqhvp - gtwlovabch) View more	-	19 Sep 2024

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data